Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence.

Trial Profile

Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 May 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Overactive bladder; Urinary incontinence
  • Focus Registrational; Therapeutic Use
  • Acronyms EMBARK
  • Sponsors Allergan
  • Most Recent Events

    • 21 May 2018 Results of a post-hoc analysis of pooled placebo-controlled trials (NCT00910845, NCT00910520, NCT01767519 and NCT01945489) assessing the risk of Clean Intermittent Catheterization, presented at the 113th Annual Meeting of the American Urological Association
    • 12 Dec 2016 Results published in the Journal of Urology
    • 09 Oct 2015 Results of post-hoc analysis presented at the 45th Annual Meeting of the International Continence Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top